Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manif...
Today, we are following up on biopharma name Aurinia Pharmaceuticals Inc. The company just posted solid Q3 results this week and announced significant cost reduction measures. Aurinia is seeing impressive sales growth, has a pristine balance sheet and should become increasingly profitable in coming years.
Aurinia Pharmaceuticals, Inc. (NASDAQ:AUPH ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Andrea Christopher - Head, Corporate Communications & IR Peter Greenleaf - President, CEO & Director Greg Keenan - Chief Medical Officer Joe Miller - CFO Conference Call Participants Stacy Ku - TD Cowen Maurice Raycroft - Jefferies Olivia Brayer - Cantor Fitzgerald Will...
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth.
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.